The Biotech Race Between the United States and China

Dear reader, imagine that today’s great-power competition is no longer only about tanks, planes, and missiles, but also about genes, medical data, vaccines, and advanced biological drugs. This is what American politician Todd Tiahrt discusses in his article, in which he describes the relationship between the United States and China as a fierce race to control biotechnology and warns that Washington could lose this race if it adopts the wrong economic policies, especially on drug pricing.

He focuses on a policy being debated in the US called the Most Favored Nation (MFN) pricing rule. On the surface, the idea looks fair and straightforward: link US drug prices to prices in other countries, usually European ones. In other words, if Germany or France pays less for the same medicine, why should American patients pay more? At first glance, that sounds reasonable, but Tiahrt argues that this kind of policy may hurt America’s ability to innovate more than it helps patients in the long run.

He explains that developing a new drug is neither easy nor cheap; it can take more than ten years and require investments of billions of dollars, with a high risk of failure at every research and clinical stage. Because of this, the whole sector depends heavily on investors’ willingness to take risks. If the government then imposes strict price controls, the expected return on that risk declines, and investors become less willing to fund pharma and biotech companies. The final result, he warns, is fewer new medicines and slower innovation, even if we don’t feel that impact immediately, but only after many years.

At the same time, the article reminds us that China is moving in the opposite direction. Beijing has declared biotech a “strategic emerging industry” and has poured billions of dollars into research cities, genome centers, and state-backed drug firms. According to the figures he cites, China now accounts for a growing share of global drug development activity and even surpasses the US in some measures of registered clinical trials. This shows that China does not want to remain just a factory producing drugs invented elsewhere; it wants to become a leading center of pharmaceutical innovation itself.

Tiahrt also highlights a key risk in global drug supply chains: China already dominates production of active pharmaceutical ingredients (APIs) and basic chemicals used to make antibiotics and many generic drugs worldwide. If the US also loses its lead in innovative and biological medicines, it could end up depending on a strategic rival for both manufacturing and innovation. That dependence becomes dangerous in times of crisis, pandemics, health emergencies, or biological threats, when access to drugs and vaccines is not only a commercial or medical issue but a national security one.

The writer then turns to America’s European allies. He argues that countries like Germany, the UK, and France have benefited for decades from drug innovation funded mainly by the US market, while using strict pricing systems that keep their own medicine prices lower than US prices. In other words, European patients enjoy drugs that were often paid for, in R&D terms, by American investors and taxpayers, but their health systems pay less. Tiahrt believes this imbalance needs to be fixed, but not by copying European price controls inside the US. Instead, he calls for trade and diplomatic negotiations that push these countries to bear a greater share of the costs of global innovation, without strangling the American research and development engine.

Domestically, he warns that an MFN-style pricing system could put tens of thousands of high-skilled jobs in the pharma and biotech sectors at risk and scare off venture capital from start-ups working on cutting-edge science. In his view, every new drug developed in an American lab is not only a scientific achievement or a profit opportunity; it is also part of the US strategic toolbox against diseases, pandemics, and biological threats, and a contributor to economic growth and exports.

In the end, he does not deny that high drug prices in the US are a real and painful problem, and that many patients suffer under heavy bills. But he sees tying US prices to foreign prices as “the wrong solution to a real problem.” Instead, he calls for reforms that improve the efficiency of the health system, review the role of middlemen and distribution chains, increase transparency in discounts and negotiations, and strengthen real competition, so the burden on patients is reduced without weakening investment in R&D.

The deeper message of the article is that scientific innovation in the twenty-first century has become a form of national defense. The country that leads the world in genomics, vaccines, and advanced therapies will be in a stronger position to protect its people and to enhance its economic and political influence. For that reason, Tiahrt warns that any policy that weakens America’s innovation capacity, even if it is marketed as a popular move to cut prices, could open the door for China to take the lead in this critical race, a race that Washington believes it simply cannot afford to lose.